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IMPROVING 
GERIATRIC DRUG THERAPY 
by GINE'ITE A. PEPPER & LAURENCE]. ROBBINS 
H ealthcare professionals and so-ciety in general harbor ambiva-
lent beliefs abom drug therapy. Mosr 
of uS anticipate that drugs will evenru-
ail}' comrol, Or eveQ cure, many age-
related dis~ases, On the mher hand, 
mere is a growing unease about the 
hazards of mediCations, which range 
from minor discomforts that diminish 
quality of life to life-threatening roxic-
iry, Some clinicians and paliems have 
responded to rhese threats with a ni-
hilistic auirude toward drugs, bur 
most recognize that rational drug 
rherapy requires weighing rhe rela-
tive risks and benefirs of each drug for 
the individual patienr. 1£ is inappro-
pnare to prescribe medications for 
each symptOm presented by lhe d-
deriy and similarly irrarional to deny 
me beneflrs of therapy to an individ-
ual merely because of advanced age, 
Inadequate research in geriatric 
pharmacology has resulted in serious 
limitarions in the dam base needed 
for making clinical decisions about 
the relative risks and benefits of drug 
therapy for the elderly, Despire the 
observation that the elderly are often 
me beneficiaries (or victims) of new 
pharmacologic agenrs, drug studies 
seldom have included subjects over 
65 years old. Even less common are 
subjects over 7S years of age, al-
though geronrologists and pharma-
cologists now recognize that re-
sponse to illness and medications is 
most likely to be alrered in thiS "old-
old" popularion. The purposes ofrhis 
an:icle are to survey rhe currem stare 
of knowledge in geriarric pharmacol" 
ogy and to amiclpare, bast:c.! upon cur-
rem issues and trends over the pasr 10 
years, the sciemific and technological 
advances likely to promOte improved 
drug therapy for the elderly in the 
next decade. 
ASSESSING BENEFITS 
It j::; imponam, but often difficult, 
[Q disringubhbcC\veen normal aging 
effects and rhe manifesrarions of dis-
ease, since: mE:diCation may be of 
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benefit in disease bur constirure only 
risk of adverse effects in its absence, 
Diagnosric criteria defined in young-
er populations may result in over-
diagnosis of the elderly. For example, 
if normS for the glucose tolerance test 
developed in 30-year-olds are applied 
to 70-year-olds, '50 percent of the el-
derly are classified as diabetic. Yet 
there is currently linle evidence to 
support the notion that vigorous con-
trol of blood glucose in the elderly 
wlll delay or prevent lethal sequelae 
such as renal failure, as such action 
mighr in young diabeti<:s (Davidson, 
1982). Indeed, anemprs to normalize 
blood glucose in older parients are 
dangerous since their blunted re· 
sponse [0 catecholamines (like epi-
nephrine rele-.lSed during stress) may 
masl< the warning signs of hypoglyce-
mia. Similar problems arise in defin-
ing and treating hypertension in the 
dderly. Whlle several srudies indicate 
that patienrs in younger populations 
benel1[ from treatment, a recent study 
of 155 subjects over 80 years of age 
suggests no reducIion from cardio-
vascular morbidiry accruing from 
treatmem of hypet1ension (Amery e[ 
al.,1986). 
Extrapolating information abom 
the benefits of drug therapy for the el-
derly from studies can be misleading, 
as exemplifed by a study of lidocaine 
for prevention and treatment of ven-
[ricular fibrillation during acuu~ 
myocardial infarction (Lie et a!., 
1974). While the study supported rhe 
effi<.:acy of rhe arrhyrhmia drug in re-
dUCing episodes of arrhythmia and 
morraliry, parients ovt:r 70 were ex-
cluded from the study. Of 141 parients 
over 70 who were excluded and un-
rreared, only one developed vemricu-
lar fibrillarion, compared ro nine of 
the 105 untreated younger subjects in 
the comrol group. Because the inci-
dence of adverse effects was 10 timt!S 
higher in [realed subjects over 60 (60 
to 69 years old) than in YOllnger pa-
liems, rhe investigaror conclucled [har 
[he benefit of rrea[menr of older pa-
[iems with lidocaine liid no! our~eigh 
the risks. UnfonunaIely, these conclu-
sions were buried in the teA10f the r-e-
pon and would not have been appar-
enr to rhe clinician who read only the 
abstract. 
Elderly patienrs often present with 
atypical signs and symproms of dis-
ease, leading to incorrect dIagnosis 
and treatmem aimed at the wrong dis-
ease. Nonspecific symproms such as 
poor appetite, falling, incontinence, 
dizziness, acme confusion, and 
weight loss may be manifeStations of 
diseases as diverse as anemia, pneu· 
mania, acute cholecystiris, and 
myocardial infarction. Failure to re-
spond to drug rherapy or drug toxic-
Iry may be harbingers of misdiagnosis 
rarher than medication ·failu·re 
(Ouslander, 1981). 
The number of studies addressing 
rhe manifestations of diseases in the 
elderly and controlled trials to deter-
mine the effects of drug treatment on 
morbidity and monaliry in thiS popu-
lation is sreadily increasing. Although 
deficits in the research base ne<:essary 
to assess the benefits of drug therapy 
will persist, clinicians will increas-
ingly be challenged to keep abreast of 
findings relevant ro clinical decision. 
making. 
ASSESSING RISKS 
Alrhough rhe elderly may be less 
likely to report adverse drug effectS 
unless specifically queStioned, slud-
ies show that they are rwo to seven 
limes more likely [0 e.xperience an 
adverse drug effecr rhan are younger 
adults (HurvvilZ, 1969; Siedl et ai , 
1966; Williamson and Chopin, 1980). 
B~cause homeosraric mechani$n1s re-
spond slowly and are less compet.em 
in older adults, an adverse drug reac-
tion that would be a minor inCOnveni-
ence to a young adult could prove cat· 
as[rophic for an elder in rhe eighrh or 
n inrh decacte (Gerber, 1982) Sevc:ra! 
faero!':'; cOntrihure lO [he higher inci-
dence of <ldv~rsc drug el'l'ecls in (he 
elderly, Ihe most impol1am of which 
is polypharmacv, or exposure ro mul· 
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tiple agents (William:>on, 1980). In ad-
dition, drugs may cornplic:ille age-
related physiologic and neuropsychi-
arric changes and iIKrease suscepti-
bilitY [0 diseas~s common among the 
elderly. 
An~icholinergic (atropine-Ii ke) 
drugs illustrate these problems. Over 
800 prescriprion and nonprescriprion 
products marketed in the United 
States, including anrihistamines, anti-
spasmodics, antidepressants, and 
antipsychOtiC agents, have anricholin-
ergic properties. Srudies indicate that 
between 30 percent and 60 percent of 
nursing home patients receive anti-
cholinergic drugs, and up to 30 per-
cent simultaneously receive two or 
more such agents (Bla2el' et aI., 1983; 
Pepper, 1985; Seifen et aI., 1983). An-
ticholinergic effects include memory 
impairmenr, confusion, alaxia (im-
paired ability ro coordina.e move-
ment), dry mouth, urinary hesitancy 
and retenrion (especially in men with 
prostatic enlargement), and consripa-
tion. The severity of some of these ef-
fects are evident-for example, uri-
nary retention, whiCh can lead ro 
renal damage-bur some of the ef-
fects, such as dry mouth, are often dis-
missed as minor inconveniences. Yet 
dry mouth call contribute to dental 
caries, denture intolerance, reduced 
raste, mucosal infections, malnutri-
tion, and difficult speech (Epslein, 
1982; ~avazesh and Ship, 1983; Todd, 
1982). Evidence that chOlinergic def-
icit is a factor in memory loss in the 
elderly and in Alzheimer's dementia 
has led to speculation that anticholin-
ergic drugs. constitllte a risk to cogni-
tive functioning in this group (Davies 
and Maloney, 1976; Sastry, 1984). One 
srudy (Pepper, 1985) suggested rhat 
use of drugs with anricho!inergic ac-
tivity increases postural sway, which 
has been linked prospectively and 
retrospeCtively to falls in the elderty 
(OverstalI, et al., 1977; Overstan, 
1980; Sheldon, 1963). 
Recognition of phySiologic alrera· 
tions of aging can aid identificaTion of 
preventable complicarions of medica-
tions. LipSitz and associates (l9S~) 
noted postprandial orthosraric de-
clines (declines when standing after 
meals) in blood pressure averaging 
15 to 25 mm Hg among nurSing home 
patients raking no amihypertensive 
medications. Prescription of antihy-
pertensive mt'dlcations ro be taken at 
mea-ltime may exacerbare these 
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ortho\taric changes, producing dizzi-
nes:>, syncope (light-headedness) , 
and risk of falls. Scheduling medica-
rion administration to minimize drug 
effects after meals and extra diligence 
in safety measures during this period 
cotlld alleviate these potential ad-
verse events. 
The elderly may demonstrate 
unique compensarory mechanisms 
rhat can be compromised by drug 
therapy. For example, in studies com-
paring cardiac function of apparemly 
healthy young and elderly peopk 
withour evidence of coronary artery 
disease, older subjects did nOt experi-
ence increased heart rate in response 
to exercise as younger subjecrs did, 
but the older subjects did have in-
creased stroke volume to sustain car-
diac output and maintain a level of ex-
ercise tolerance comparable to .he 
yOunger subjecr.~ (Rodeheffer et aI., 
1984). Therefore, drugs such as beta-
adrenergic receptor blockers and cal· 
cium channel antagonists, which de-
crease myocardial contractility 
(stroke volume), may have grearer 
tOxicity in the elderly who are more 
dependent on myocardial contractU-
iry to meet increased cardiac de-
mands during (;!xercise. 
Drug interactions. Drug interac-
rions coosticu[e a subset of adverse 
drug reactions, and mulridrug ther-
apy obviously increases the risk of 
this problem. While rhe inCidence of 
drug interaction may be as high as 9 
percent for hospitalized elders re-
ceiving two Or more drug.~, less than 1 
percent are in danger of serious se-
quelae due to drug imeractions. The 
risks for life-rhreatening reactions 
may be higher, however, for elderly 
residems in longterm·care sertings 
(Lamy, 1986). Because of age-related 
changes in drug dispOsition (see be-
low), older patients appear to be 
more susceptible than younger pa-
rients to drug interacrions resulring 
from competition for albumin bind-
ing (such as hypoglycemia from the 
interaction of the oral antidiabetic 
agent, tOlbutamide, and sulfonamide 
antibiotics) and those resulting from 
inhibition of microsomal enzymes 
(such as decreased metabolism of 
diazepam when concurrently admin-
istered wirh cimetidine). However, 
the elderly appear to be less likely to 
develop clinically significam effects 
from drug interaCtions involving the 
induction of microsomal enzymes 
(such as increased theophylline me-
tabolism in smokers) (jennings c:C al., 
1985; Vestal, 1982). 
Som~ of [he drug imerac[ions may 
be quite complicated, such as rhe in-
creased hypoprothrombinemic ef-
fecrs of warfarin when coadminis" 
lered with sulindac. This interacrion 
occurs only in patients having a defecr 
in the mbular secretion of potassium 
that causes decreased clearance of 
sulindac, enhancing the activiry of 
warfarin (Garella and Matarese, 
1984). 
CompLiance. Noncompliance and 
errors in self-administration of drugs 
consrirure another pOtential risk of 
drug therapy. Many srudies indicate 
thac 40-50 percent of patients do nor 
take medicarions as prescribed. I[ is 
commonly thought that older patients 
are more prone ro noncompliance, 
although several studies dispute this 
presumption (German et al., 1982). 
There are manv reasons for the fail-
ure of an elderly person (Q take mc;di-
cations as intended by the prescriber. 
Prescriprion of multiple medications 
or complex regimens contribute Sig-
nificantly ro noncompliance. Wein-
[raub and asSOCiates (1973) idemified 
a compliance rate of 82 percem for 
patients raking only digoxin, but the 
rate declined to 60 percem when the 
regimen also included a diuretic and 
pOtassium. Hence, the prescription of 
"benign" drugs (those that can nor do 
any harm and may do some good) ac-
rually may compromise the effective-
ness of crucial therapy. 
Besides complex regimens, faaors 
rhat compromise compliance are the 
use of child-proof containers, confus-
ing insrrucdons given verbally Or 
wrirten on the label, inabiliry to swal-
Iowa large tabler, and hoarding of old 
medications (Anderson, 1974). How-
ever, intentional' noncompliance i" 
very commOn \n [he elderly and may 
at times be appropriate (Cooper er 
aL, 1992). 
In summary, the pOtential risks of 
drug Therapy in die elderly are di-
verse and complex, ranging from 
side-effects to drug imeractions and 
noncompliance. Much remains un-
known about the incidence of specific 
adverse drug effecrs and effecrive 
methods [b· minimize rhese risks. r"ur-
ther, smdies have nor consistently 
documented that decreasing the 
number of medicatiOns, patient edu-
cation, or memory aids improve com-
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pliance in the elderly (German et aL, 
1982). Umil [here are consiStency and 
rigor in the definition and measure-
ment of adverse dmg effectS, of com-
pliance, and of clinically significant 
dmg imeractions, divergem conclu-
sionS will coorinue m characterize reo 
s(;!arch on this aspect of geriatric pharo 
macology. 
DRUG DISPOSITION 
Research in geriatric pharmacol-
ogy is best esrablished in the specialty 
of pharmacokinetiCS (disposition of 
drug by the body). Progress in this 
area over the pasr decade has been re-
markable, and this trend is likely to 
continue with the implememarion of 
proposed Food and DmS Administra-
tion guidelines for clinical evaluation 
of drugs being developed for use in 
the elderly. In the early 19705, rhe 
state of knowledge abom pharmaco-
kinetics and pharmacodynamics (ac-
[ion of drug on the body) conslsred 
primarily of the foHowlng: findings 
that most 9rugs tested had prolong~d 
half-lives in ehe elderly, a deduaion 
that renal clearance of drugs was re-
duced, a suspicion (hat the elderly 
were more senSitive to many agents, 
and evidence that the elderly demon-
strated an incredible amoum of diver-
sity in all aspeCtS of pharmacology. 
There was little guidance mar could 
be offered the clinician except me 
warning to "srarr low and go slow" 
under [he presumption that pro· 
longed drug half-life always required 
reduced loading and mainrenance 
doses. 
Over the past decade much of the 
variance in the response of me el-
derly to medications has been ex-
plained, but ir is still evident that 
older people are a~ diverse in pharo 
macologic parameters as [hey are in 
other physiologic and neuropsychiar-
ric functions. Age-relared changes 
once thought to he significant in al-
cered drug response have proven un-
imporranr. For example, during aging 
there are many physiologic changes 
of rhe gaseroimestinal tract that theo-
retically could alter drug absorprion, 
bur no clinically significant alteration!> 
in absorption have been idemified in 
[he elderly, except when there is con-
comi[ant diSease Or c!rug lllerapy 
such ;1S antacids (GrcenbJan er al. , 
1982). 
Similarly, d~crea5ed serum al-
bumin concentration thar occurs in 
aging and resultS in significant de· 
crease in the ratio of bound to free 
(active) drug has frequently been 
cited in explanation for increased 
drug response. However, since both 
the clearance and effects of drugs are 
related to the free-drug concemra-
tion, the steady-state (homeostasiS, Or 
balance, within the body) effectS and 
maintenance dose regimen should 
not be altered by serum albumin 
changes alone, unless there is also de-
creased drug elimination (Gerber, 
1982; Katzung, 1987). Altered al· 
bumin binding may explain in· 
creased suscepribiliry ro drug interac-
tions resulting from comperition for 
protein binding and may also alter 
loading dose and the interpretation of 
laborarory delerminations of blood 
levels of drugs. When interpreting 
blood levels of highly albumin·bound 
drugs which generally measu~e both 
bound and free fractions of the drug, 
consideration must be given to the 
face that lower levels may be thera-
peutic since there is a higher ratio of 
free drug. 
Early findings of p~olonged half-
lives of drugs in [he elderly offered lit-
tle guidance!O seleCting drug dosage, 
since both increased volume of diStri· 
bution and decreased clearance 
result in prolonged half-life. How. 
ever, volume of diStribution affects 
the loading dose, while clearance de-
[ermines the maintenance dose, so 
dle clinical implications of prolonged 
half-life depend upon the paramerer 
altered by the aging process. For ex-
ample, ehe inCrease in gentamicin 
half-life common among the elderly 
is due predominantly to decreased 
clearance, so the weight-adjusted 
loading dose is the same for younger 
and older parients, bur the maime-
nance dose ofi;en must be smaller for 
older patients (Gerber, 1982). 
The distribution characteristics of 
drugs are altered by aging. Most obvi-
ous is the fact that the elderly are uSu-
ally smaller than younger patients. 
funher, in aging there is a shift in 
body composi,ion, with an increase 
in fat mass and a decrease in lean 
mass. Far-soluble drugs have larger 
v(»)umes of distribution io the elderly, 
require larger relative loading doses, 
and are slower to approximate steadv 
state (Jennings et aI., 1985) for exam-
ple, most of rhe increased average 
hllf-life of diazepam, from 20 hou-r5 
in young adults to 80 hourS in elderly 
adultS, Is due {Q the increased volume 
of distribution. This explains a fre-
quent clinical phenomenon where 
the elderly patient, whose anxiety or 
agirarion was poorly controlled dur-
ing the initial days of therapy, be-
comes somnolent after a w~k or 
more on diazepam or other central-
nervous~system depressant. Since av-
erage blood levels continue to rise 
until rhe drug approximares steady 
state (four to five half-lives), and the 
diazepam will not reach steady State;: 
for 320 to 400 hours, the full clinical 
impacr of such drugs may be -delayed. 
Metabolic clearance of SOme drugs 
changes with aging, while metabo-
lism of many drugs is unaffected. 
However, the decremenrs in renal 
function are so consistent among the 
elderly that any drug eliminated 
greater than 20 percent unchanged 
(acrive) in the urine should probably 
be administered in lower initial main-
tenance dosages in the elderly. 
Ir is now recognized that most of 
me apparem changes in sensitivity of 
the elderly to drugs are due to phar-
macokinetic 'Changes and diminished 
homeostatic responses. However, 
studies have documented decreased 
responsiveness ro dntgs mar work at 
the bera-adrenergic receptor, includ-
ing beta stimulants and beta blockers 
(V.esral .et a!., 1978). These decr.e-
ments have been linked to receptor-
effe<:tOr coupling rather man [Q al-
rered recepror function, however. 
Similarly, the increased incidence of 
bleeding nOted wirh anticoagulant 
therapy in elderly patients is attrib-
uted more to diminished capaciry of 
degenerated vessels to achieve me-
chanical hemostasiS, a homeostatic 
response, rather than to increased re-
ceptor sensitiVity. 
New dosage forms. Technological 
advances in drug delivery systems of-
fer less frequent dOSing, more ~On­
sistem blood levels, and fewer ad-
verse effects because the total dosage 
is often less than was required with 
older dosage forms. ln addition, there 
are fewer problems relared [Q con-
comiran[ food and drug intake. These 
advantages may decrease noncomph-
ance and provide improved diseasl: 
COntrol. Examples of these new SyS-
tems include liquid digoxin in gelatin 
capsules, in Wllich imprOved solubil-
ity provides aboLlt 25 percenr in-
creased bioavailabiliry and possibly 
more conSiStent absorption. Coating 
S9 
drugs wirh waxes, cellulose films, and 
pOlymers has resu Ited in a group of 
long-aGing tablets. Systems using 
polymeric membranes and Ion ex-
change mechanisms m deliver drugs 
ar a predetermined rate over an ex-
tended period (controlled release) 
are currently available orally for ami-
histamines and narcorics and topi-
ca:lJy for nitroglycerin, pilocarpine, 
scopalomine, estrogen, and orhers. 
Projecred for the fufUre are transder-
mal systems that can deliver tWO 
drugs.. a[ different rates and artifiCial 
phospholipid vesicles called liposo-
mes that enhance cellular drug up-
rake (Alper, 1985; Hi1d~brand, 1983; 
Maierhofer, 1985; Pepper, 1986). 
Such technological advances nor 
only hold promise for the elderly, but 
they also present a group of new di-
lemmas, Altered dermal anatomy and 
gastrointestinal function wim aging 
may affect the performance of drug 
delivery systems in the elderly. Since 
these systems often deliver reduced 
drug dosages, the time required to 
deliver the loading dose and achieve 
steady state may also be prolonged, 
RECOMMENDATIONS 
While me knowledge base regard-
ing pharmacology in the elderly has 
expanded ' over the last decade and 
will undoubtedly increase rapidly in 
the future, the fact remains that the 
most consistent characteriStic of the 
elderly is diversity. For each patient 
there is a unique set of biologic, path-
ologiC, and psychosocial factOrs af-
fecting drug response and requiring 
an individualized approach. For ex-
ample, although renal funCtion de-
clines ail average of 50 percent be-
tween the ages of 20 and 80, some 
80-year-oldS have "normal" creati-
nine clearance and would nOt re-
spond to reduced dosages of drugs. 
Improving drug therapy for the el-
derly is. increasingly a znultidiscipli~ 
nary responsibility. The prescriber 
(physician, dentist, podiatrist, nurse 
practitioner, and the like) has me re-
sponSibilities of accurate diagnosiS, 
drug seleCtion, and commun.(cation 
of rbe expected lberapeu.nc outcomes 
to other members of the healthcare 
team, induding [he patient, Through 
awareness. of the specific desired OUt-
come of each drug, all members of 
the ~eam can apply their unique skills 
to prornOtt; the therapeutic cffc::c[, to 
recognize situations where the risks. 
60 
oLJ[Weigh the achieved or desired 
oU[come5, and [0 propose nonphar-
macologic alternatives if appropriate, 
Clinical pharmacists have demon· 
s[raced imporram comributions 
through identification of clinically 
significam drug interactions and con-
sultation on drug selecrion, While iC is 
widely accepted rhat the safest way co 
prescribe for the elderly is [Q sran 
with small doses and ritrate (move up 
slowly so the deSired response is 
achieved with me smallest amount of 
substance necessary) ("start low and 
go slow"), hospitalizations are usually 
tOo short to complete the tirration, 
and the frequent returns to clinic or 
office for monitoring may constitute 
a problem for patient and prescriber, 
In many settings, such as the home, 
nursing homes, and dinics, nurses 
have assurtled the responsibility for 
moniroring and titraring drug dos. 
ages within rhe goals and protocol es-
tablished by the prescriber. Noncom-
pliance is another problem amenable 
to a team approach, especially if the 
patient is a partiCipant. Commonly 
overlooked as an effective way to as-
sess compliance is [0 ask the patient; 
the patient will generally explain not 
only whether he or she is taking the 
drug as ordered but also the re".1Son 
for: any noncompliance, Improving 
drug therapy is a complex objective, 
achievable through coordinated 
effort, • 
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Innovations in Homecare 
The recent growth 
in home bealthcare 
bas been coupled with 
phenomenal developments 
in technology and 
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T e inStinctive deSire to reo main in one's own home can result in rhe freedom, dignity, and comfon: [hat 
accompanies independent living. Pa· 
tient acceprance of and deSire for 
homecare as an alternative [(l insritu-
tional care is well known, as is the 
general :mimde among the public 
and healthcal"e professionals [har 
nursing homes, however well run, 
are places of la"t reSOrt. The tendency 
for pari ems to receive more care at 
home has been increasing and is ac-
companied by a high degree of satis-
faction, bur enthusiasm has been tern· 
pered by concern over availabiHty of 
resources in [he community to pro-
vide the necessary :mpport (both 
medical and social). 
As longeviry increases and our 
medical technology provides at leaSt 
partial control of Some serious ill· 
nes:>es, [he complexiry of care reo 
qulred for optimal funcrloning of rhe 
individual also increases. When the 
goal i!' independent living and home-
care is considered as an alternative to 
nursing hOme care, Or as a WilY to 
avoid premarure nursing home place-
ment. then the suppOrt services re-' 
quired encompass a broad contin-
uum of types of care and include 
social support as well as healthcare. 
To add to the problem, Societal is-
sues of co~r conwinmenr, individu<ll 
righb, per:>onal dignity and freedom 
of choice, and access to healrhcare of-
{en produce conflicring public policy, 
legislation. and regulatiOns. For ex· 
ample, effortS at -COntainment of hos-
pir~l -COStS utilizing prospective re-
imbursemem (diagnosis-related 
groups, or DRGs) have provided rna· 
jor motivation for earlier discharge of 
parienrs. As a result, manv of th~se pa· 
tients may have significam needs for 
homecare in order to either make a 
successful recovery from illness or 
maximize potential for remaining at 
home. HOwever, these needs arise as 
COst·containment policies are also ad-
versely affecting ac.cess to incr~ased 
amounts of homecare. 
Looking at the growth of rhe el-
derly in our population, with their inr 
creased disability ( 46 percent of those 
over the age of 75 have major Iimita· 
tiOns in their abilities to perform ac-
{iviCies of daily living) (U.S. Senate, 
1984), the need for mainrenance care 
for chronic illness is apparent How-
ever, the current system, with Medi-
care as the protoryp'e, still has much of 
its focus on [he provision of acute 
care, whether at home or in an institu-
tion. Current reimbursemem meth-
ods that dictate t)(pes and amounts of 
homecare, set spending-caps, and re-
quired multiple funding sources have 
all hindered the development of a co-
hesive, coordinated syst~m for the 
provision of longrerm care. 
It is in this setting [hat homecare 
has undergone tremendous growth, 
developmenr, and change over the 20 
years since the introduc,ion of r.kdi-
care. The innovarions [hat have oc-
curred can be grouped into three 
bro~\d areaS: medical technologv (in-
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